Form D — Uvantis Therapeutics, Inc.
0002156954-26-000001 · filed Sep 23, 2026
Offering
- Industry
- Biotechnology
- Exemptions
- 06b
- Total offering
- $5,000,000
- Total sold
- $100,000
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Uvantis Therapeutics, Inc.
- CIK
- 2156954
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2025
- Address
- 10980 GRANTCHESTER WAY
COLUMBIA, MD 21044 - Phone
- 6174176695
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
William Sheahan · DirectorColumbia, MD Find on LinkedIn ↗
-
Jonathan Young · DirectorColumbia, MD Find on LinkedIn ↗
-
Edward Woo · DirectorColumbia, MD Find on LinkedIn ↗
-
Paul Giannasca · Executive OfficerColumbia, MD Find on LinkedIn ↗
-
Jeffrey Collins · Executive OfficerColumbia, MD Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗